Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells

被引：0
|
作者：
Yue-qin Wang
Ai-jun Shen
Jing-ya Sun
Xin Wang
Hong-chun Liu
Min-min Zhang
Dan-qi Chen
Bing Xiong
Jing-kang Shen
Mei-yu Geng
Min Zheng
Jian Ding
机构：
[1] China Pharmaceutical University,Department of New Drug Screening Center
[2] Division of Anti-tumor Pharmacology,Department of Thoracic Surgery
[3] Synthetic Organic and Medicinal Chemistry Laboratory,undefined
[4] State Key Laboratory of Drug Research,undefined
[5] Shanghai Institute of Materia Medica,undefined
[6] Chinese Academy of Sciences,undefined
[7] Shanghai Tongren Hospital,undefined
[8] Shanghai Jiao Tong University School of Medicine,undefined
来源：
Acta Pharmacologica Sinica | 2016年 / 37卷
关键词：
non-small cell lung cancer; gefitinib resistance; Hsp90;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1587 / 1596
页数：9
相关论文
共 50 条
  • [1] Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells
    Wang, Yue-qin
    Shen, Ai-jun
    Sun, Jing-ya
    Wang, Xin
    Liu, Hong-chun
    Zhang, Min-min
    Chen, Dan-qi
    Xiong, Bing
    Shen, Jing-kang
    Geng, Mei-yu
    Zheng, Min
    Ding, Jian
    ACTA PHARMACOLOGICA SINICA, 2016, 37 (12) : 1587 - 1596
  • [2] Author Correction: Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells
    Yue-qin Wang
    Ai-jun Shen
    Jing-ya Sun
    Xin Wang
    Hong-chun Liu
    Min-min Zhang
    Dan-qi Chen
    Bing Xiong
    Jing-kang Shen
    Mei-yu Geng
    Min Zheng
    Jian Ding
    Acta Pharmacologica Sinica, 2020, 41 : 731 - 732
  • [3] Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells (vol 37, pg 1587, 2020)
    Wang, Yue-qin
    Shen, Ai-jun
    Sun, Jing-ya
    Wang, Xin
    Liu, Hong-chun
    Zhang, Min-min
    Chen, Dan-qi
    Xiong, Bing
    Shen, Jing-kang
    Geng, Mei-yu
    Zheng, Min
    Ding, Jian
    ACTA PHARMACOLOGICA SINICA, 2020, 41 (05) : 731 - 732
  • [4] Targeting KRAS-Mutant Non-Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
    Acquaviva, Jaime
    Smith, Donald L.
    Sang, Jim
    Friedland, Julie C.
    He, Suqin
    Sequeira, Manuel
    Zhang, Chaohua
    Wada, Yumiko
    Proia, David A.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (12) : 2633 - 2643
  • [5] Chalcone-templated Hsp90 inhibitors and their effects on gefitinib resistance in non-small cell lung cancer (NSCLC)
    Ju Hui Jeong
    Yong Jin Oh
    Taeg Kyu Kwon
    Young Ho Seo
    Archives of Pharmacal Research, 2017, 40 : 96 - 105
  • [6] Chalcone-templated Hsp90 inhibitors and their effects on gefitinib resistance in non-small cell lung cancer (NSCLC)
    Jeong, Ju Hui
    Oh, Yong Jin
    Kwon, Taeg Kyu
    Seo, Young Ho
    ARCHIVES OF PHARMACAL RESEARCH, 2017, 40 (01) : 96 - 105
  • [7] Discovery of Licochalcone A as a Natural Product Inhibitor of Hsp90 and Its Effect on Gefitinib Resistance in Non-Small Cell Lung Cancer (NSCLC)
    Seo, Young Ho
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2013, 34 (06) : 1917 - 1920
  • [8] Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib
    Naito, Yoichi
    Goto, Koichi
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1027 - 1040
  • [9] Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer
    Mao, Jianhua
    Ma, Lie
    Shen, Yan
    Zhu, Kongkai
    Zhang, Ru
    Xi, Wenda
    Ruan, Zheng
    Luo, Cheng
    Chen, Zhu
    Xi, Xiaodong
    Chen, Saijuan
    CELL DEATH & DISEASE, 2018, 9
  • [10] Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer
    Jianhua Mao
    Lie Ma
    Yan Shen
    Kongkai Zhu
    Ru Zhang
    Wenda Xi
    Zheng Ruan
    Cheng Luo
    Zhu Chen
    Xiaodong Xi
    Saijuan Chen
    Cell Death & Disease, 9
12345